Department of Pathology, University of Manitoba, Winnipeg, Canada.
Department of Pathology, Western University, London, Canada.
Int J Surg Pathol. 2024 Oct;32(7):1292-1302. doi: 10.1177/10668969241228290. Epub 2024 Mar 18.
SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are a newly described entity and are typically seen in the thoracic cavity. However, these tumors have been described in other body sites, including the esophagus. These tumors are rare, aggressive neoplasms, characterized by the loss of protein product of SMARCA4 (Brahma-related gene-1) and the preservation of INI1 (SMARCB1) expression. Here, we present two tumors of SMARCA4-UT of the esophagus with its microscopic appearance and immunohistochemical profile. We also include a literature review of SMARCA4-deficient tumors of the tubular gastrointestinal tract with their immunohistochemical and mismatch repair profiles for each specimen. Due to its non-specific histologic appearance and variable staining in expanded immunohistochemical panels, this tumor frequently overlaps with other tumor types, making the diagnosis of SMARCA4-UT challenging. These tumors are often associated with intestinal metaplasia of the esophagus and are thought to represent a high-grade undifferentiated transformation of a conventional esophageal adenocarcinoma. These tumors are typically associated with poor clinical outcomes and have poor response to conventional therapies. Currently, there are no standard guidelines for treatment of these tumors; however, palliative radiotherapy and systemic chemotherapy may provide benefit. More recently, immunotherapy and novel therapeutic targets have shown some promise for these patients.
SMARCA4 缺陷未分化肿瘤(SMARCA4-UT)是一种新描述的实体,通常见于胸腔。然而,这些肿瘤也已在其他身体部位被描述,包括食管。这些肿瘤是罕见的、侵袭性的肿瘤,其特征是 SMARCA4(Brahma 相关基因-1)的蛋白产物缺失,同时保留 INI1(SMARCB1)的表达。在此,我们展示了两个食管 SMARCA4-UT 肿瘤的微观表现和免疫组织化学特征。我们还对管状胃肠道的 SMARCA4 缺陷肿瘤进行了文献复习,包括每个标本的免疫组织化学和错配修复特征。由于其非特异性的组织学外观和扩展的免疫组织化学面板中的可变染色,这种肿瘤经常与其他肿瘤类型重叠,使得 SMARCA4-UT 的诊断具有挑战性。这些肿瘤通常与食管的肠上皮化生有关,被认为是一种常规食管腺癌的高级未分化转化。这些肿瘤通常与不良的临床结果相关,对常规治疗反应不佳。目前,这些肿瘤的治疗尚无标准指南;然而,姑息性放疗和全身化疗可能会带来益处。最近,免疫疗法和新型治疗靶点为这些患者带来了一些希望。